The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Open accessAbstract
BACKGROUND: Closed-loop systems that automate insulin delivery may improve glycemic outcomes in patients with type 1 diabetes. METHODS: In this 6-month randomized, multicenter trial, patients with type 1 diabetes were assigned in a 2:1 ratio to receive treatment with a closed-loop system (closed-loop group) or a sensor-augmented pump (control group). The primary outcome was the percentage of time that the blood glucose level was within the target range of 70 to 180 mg per deciliter (3.9 to 10.0 mmol per liter), as measured by continuous glucose monitoring. RESULTS: A total of 168 patients underwent randomization; 112 were assigned to the closed-loop group, and 56 were assigned to the control group. The age range of the patients was 14 to 71 years, and the glycated hemoglobin level ranged from 5.4 to 10.6%. All 168 patients completed the trial. The mean (±SD) percentage of time that the glucose level was within the target range increased in the closed-loop group from 61±17% at baseline to 71±12% during the 6 months and remained unchanged at 59±14% in the control group (mean adjusted difference, 11 percentage points; 95% confidence interval [CI], 9 to 14; P<0.001). The results with regard to the main secondary outcomes (percentage of time that the glucose level was >180 mg per deciliter, mean glucose level, glycated hemoglobin level, and percentage of time that the glucose level was <70 mg per deciliter or <54 mg per deciliter [3.0 mmol per liter]) all met the prespecified hierarchical criterion for significance, favoring the closed-loop system. The mean difference (closed loop minus control) in the percentage of time that the blood glucose level was lower than 70 mg per deciliter was -0.88 percentage points (95% CI, -1.19 to -0.57; P<0.001). The mean adjusted difference in glycated hemoglobin level after 6 months was -0.33 percentage points (95% CI, -0.53 to -0.13; P = 0.001). In the closed-loop group, the median percentage of time that the system was in closed-loop mode was 90% over 6 months. No serious hypoglycemic events occurred in either group; one episode of diabetic ketoacidosis occurred in the closed-loop group. CONCLUSIONS: In this 6-month trial involving patients with type 1 diabetes, the use of a closed-loop system was associated with a greater percentage of time spent in a target glycemic range than the use of a sensor-augmented insulin pump. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases; iDCL ClinicalTrials.gov number, NCT03563313.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The largest trial with this class in T1D was with liraglutide, which showed a reduction of A1C of 0.4% with the highest 1.8 mg dose in addition to a 5 kg weight loss and insulin dose reductions.1177”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1177]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, the introduction of CGM devices that alarm with low blood glucose concentrations and semiautomated pumps that suspend insulin infusion as glucose concentrations decrease have facilitated achieving target HbA 1c levels with less risk for hypoglycemia (332).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [332]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hybrid closedloop systems are the most effective means of maintaining glucose in the normal range in people with type 1 diabetes (90,91).”
From The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2021) · cites this paper as [91]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of insulin analog regimens are associated with less hypoglycemia, while hybrid closed-loop systems result in both improvement in TIR and reduction in TBR (91).”
From The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2021) · cites this paper as [91]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These prestigious publications reported pivotal trials of the commercial descendant of DiAs-a new AID system (Control-IQ by Tandem Diabetes Care)-in different age groups: 14 years old and older, 132 6 to 13 years old, 133 and 2 to 6 years old.134”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [132]
The cited source says what the claim attributes to it.
In the citing paper
“This large-scale study and its continuation with young children ages 2 to 6 years old completed several clinical protocols, three of which were published in the New England Journal of Medicine.[132][133][134]”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [132]
The cited source says what the claim attributes to it.
In the citing paper
“In particular, glucose time in range (70 -180 mg/dl [3.9 -10.0 mmol/l]) and time in hypoglycemia ( < 70 mg/dl [3.9 mmol/l] and < 54 mg/dl [3.0 mmol/l]) have been used as outcomes for clinical trials 259,260 and have been endorsed as appropriate metrics for clinical care. 229”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [260]
The cited source says what the claim attributes to it.
In the citing paper
“Evidence suggests that an AID hybrid closed-loop system is superior to AID sensor-augmented pump therapy for increased percentage of time in range and reduction of hypoglycemia (34,35).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [34]
The cited source says what the claim attributes to it.
In the citing paper
“HbA 1c , TIR, and TBR are improved further when physiological MDI or pump regimens are augmented with CGM usage (89), with the greatest benefits seen with algorithm-driven automated basal (and in some systems correction) insulin delivery, which is commonly called hybrid closed-loop therapy (90,91).”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although this agent was more effective with those participants still producing endogenous insulin, the added hypoglycemia and ketosis noted has resulted in no attempt for FDA approval in T1D.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1177]
Experimental — accuracy not yet measuredIn the citing paper
“all AID system pivotal trials that examined individuals 2 years old or older, including older adults, have consistently demonstrated superiority to either standard insulin delivery (or manual mode for the single-arm studies) or SAP and/or usual care (for the randomized trials)”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [208]
In the citing paper
“with consistent improvement in A1C, increase in TIR, especially overnight, as well as reduction of time spent in hypoglycemia (207-219).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [208]
In the citing paper
“with consistent improvement in A1C, increase in TIR, especially overnight, as well as reduction of time spent in hypoglycemia (207-219).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [208]
In the citing paper
“with consistent improvement in A1C, increase in TIR, especially overnight, as well as reduction of time spent in hypoglycemia (207-219).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [208]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
Foster, N. C., Beck, R. W., Miller, K. M., Clements, M. A., Rickels, M. R., DiMeglio, L. A., Maahs, D. M., Tamborlane, W. V., Bergenstal, R., Smith, E., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0384 · Cited by 1,907
Self-citation6. Glycemic Targets: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s006 · Cited by 655
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644
Self-citationWeisman, A., Bai, J.-W., Cardinez, M., Kramer, C. K., & Perkins, B. A. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30167-5 · Cited by 463
Tauschmann, M., Thabit, H., Bally, L., Allen, J. M., Hartnell, S., Wilinska, M. E., Ruan, Y., Sibayan, J., Kollman, C., Cheng, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31947-0 · Cited by 440
Self-citationBekiari, E., Kitsios, K., Thabit, H., Tauschmann, M., Athanasiadou, E., Karagiannis, T., Haidich, A.-B., Hovorka, R., & Tsapas, A. (2018) · BMJ · doi:10.1136/bmj.k1310 · Cited by 437
Kleinman, L. C., & Norton, E. C. (2008) · Health Services Research · doi:10.1111/j.1475-6773.2008.00900.x · Cited by 287
Forlenza, G. P., Li, Z., Buckingham, B. A., Pinsker, J. E., Cengiz, E., Wadwa, R. P., Ekhlaspour, L., Church, M. M., Weinzimer, S. A., Jost, E., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0771 · Cited by 246
Self-citationBenhamou, P.-Y., Franc, S., Reznik, Y., Thivolet, C., Schaepelynck, P., Renard, E., Guerci, B., Chaillous, L., Lukas-Croisier, C., Jeandidier, N., et al. (2019) · The Lancet Digital Health · doi:10.1016/s2589-7500(19)30003-2 · Cited by 217
Flagged first, then by citations
Cited by
Sorted by citations
Items 901–999 of 999
(2024) · American Diabetes Association eBooks · doi:10.2337/9781580408363.ch05
(2021) · American Diabetes Association eBooks · doi:10.2337/9781580407694.ch07
Patient Selection, Clinical Considerations, and Intensive Diabetes Management Goals
(2021) · American Diabetes Association eBooks · doi:10.2337/9781580407694.ch05
Tecnología aplicada a la diabetes
Cebada, A. B., Silva, J. B. Q., Escobar-Morreale, H. F., & Chávez, L. N. (2024) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2024.10.004
Automatische Insulinabgabe: Was heute möglich ist
Thomas, A. (2024) · Info Diabetologie · doi:10.1007/s15034-024-5039-2
Impacto del inicio de la monitorización flash de glucosa en pacientes adultos con diabetes tipo 1
Sahagún, R. J. (2024) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/72390
Hussain, I., MacLeod, J., Dunn, F., Bickel, P. E., Abreu, M., McNulty, N., Lingvay, I., Kermani, A., & Abreu, M. (2020) · American Diabetes Association eBooks · doi:10.2337/9781580406314.ch03
Advanced sensors for smart drug delivery
Ünlü, B., Türk, S., Çakar, S., & Özacar, M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-24790-3.00015-6
(2022) · American Diabetes Association eBooks · doi:10.2337/9781580407700.ch03
(2022) · American Diabetes Association eBooks · doi:10.2337/9781580407700.ch04
Cloud computing- and digital twin-based monitoring framework for healthcare applications
Li, Z., & Sun, T. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-34226-4.00022-8
Sobczak, M., Pyle, L. L., Sawyer, A., Forlenza, G. P., & Alonso, G. T. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0500
Self-citation(2025) · Elsevier eBooks · doi:10.1016/b978-3-437-21835-4.00116-5
A clinical case of the use of a closed loop system in the treatment of type 1 diabetes mellitus
Teplova, A. S., Parkhomenko, A., & Petrosyan, K. (2025) · FOCUS.Endocrinology · doi:10.62751/2713-0177-2025-6-2-11
Aggas, J. R. (2025) · Biosensors and Bioelectronics X · doi:10.1016/j.biosx.2025.100676
Anandhakrishnan, A., Liarakos, A. L., Dhatariya, K., Gallen, G., Choudhary, P., Lumb, A. N., Wilmot, E. G., & Hussain, S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70027
Everett, E. M., Tiu, R. A.-Y., Zhu, B., Feng, J., JACKSON, N. J., Graham, J., Ipp, E., Mathioudakis, N. N., Bui, A. A. T., & Moin, T. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251383828
X-ray durability of continuous glucose monitoring sensors during pseudo-measurement
Matsubara, H., Sagara, K., & Shimotake, S. (2025) · Radiation Physics and Chemistry · doi:10.1016/j.radphyschem.2025.113370
Kumar, S., AAKASH, F., Kumari, N., Lohana, C. K., Abbas, A., Gyaneshwari, F. N. U., Kumari, R., Eman, F. N. U., Bai, R., Syed, S., et al. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70127
Neue Therapieoptionen bei Diabetes mellitus Typ 1
Arndt, S. V. (2025) · Journal für Endokrinologie Diabetologie und Stoffwechsel · doi:10.1007/s41969-025-00289-z
Pawar, A. D., Rohile, S. B., & D., P. S. S. (2025) · International Journal of Advanced Research in Science Communication and Technology · doi:10.48175/ijarsct-29628
Moreno-Fernández, J., López, L. M., Maqueda, E., Quiroga, I., González, J., Marco, A., Herranz-Antolín, S., Martínez, A., Edith, D., González-Maroto, I., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-22666-z
Pharmacologic Therapy for Type 2 Diabetes
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch04
Pharmacologic Therapy for Type 1 Diabetes
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch01
Shibah, S. R. M. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5917523
Kang, S. L., Hwang, Y. N., Kwon, J. Y., & Kim, S. M. (2024) · Figshare · doi:10.6084/m9.figshare.26552224
Godoi, A., Reis Marques, I., Padrão, E. M. H., Mahesh, A., Hespanhol, L. C., Riceto Loyola Júnior, J. E., de Souza, I. A. F., Moreira, V. C. S., Silva, C. H., Miyawaki, I. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26620396
Nowacka, K., Grygorowicz, A., Baran, K., Ględa, M., Szyszka, M., Radecka, W., Kozak, W., Szreiber, A., Grela, K., Jabłoński, K., et al. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4660
Diabetes & Technik: Chancen bei Sprachbarriere
Aydınkoç-Tuzcu, K., Kietabl, A.-T., Frühwald, L., & Fasching, P. (2025) · Die Diabetologie · doi:10.1007/s11428-025-01405-y
Brothers, J. (2026) · Physician Assistant Clinics · doi:10.1016/j.cpha.2025.10.001
Chrzanowski, J., Olejniczak, A., Różycka, P., Michalak, A., Fendler, W. M., & Szadkowska, A. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251390825
Artificial Intelligence in In Vitro Diagnostics (IVD): A Comprehensive Review of the New Frontier
Ngoc, H. L. (2026) · IEEE Access · doi:10.1109/access.2026.3660065
Glycemic management in adults with type 1 diabetes
Koliaki, C. C., & Liatis, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00317-4
Propper‐Lewinsohn, T., Elran‐Barak, R., Gillon‐Keren, M., Yackobovitch‐Gavan, M., Liberman, A., Phillip, M., & Shalitin, S. (2026) · Hormone Research in Paediatrics · doi:10.1159/000550948
Zaharieva, D. P. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00406-1
AEGIS: AI-Driven Glucose Prediction and Personalized Insulin Dosing
Pansheriya, Y. K., & Asadinia, M. (2026) · IEEE Annual Computing and Communication Workshop and Conference (CCWC) · doi:10.1109/ccwc67433.2026.11393699
Yang, Y., Liu, Z., HUANG, Y. ‐., Deng, H., Yang, X., Yan, J., Zeng, L., Lin, B., & Xu, W. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02204-2 · Cited by 1
Kidney and Cardiovascular Protection in Diabetes: Beyond Diabetes Typology
Mottl, A. K., Sawinski, D. L., & Bjornstad, P. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.10.022
Automated Insulin Delivery for Patients with Type 2 Diabetes: A Narrative Review
Kitsios, K., & Trakatelli, C. (2026) · Current Diabetes Reviews · doi:10.2174/0115733998418695251203105337 · Cited by 1
ALAIMO, C. G., BIANCHI, F., Mancin, S., FIDATO, B., Cattani, D., Valsecchi, A., Chiari, C., Cangelosi, G., Parozzi, M., Scollo, S., et al. (2026) · Minerva Gastroenterology · doi:10.23736/s2724-5985.26.04089-1
Bilal, A., Horton, W. B., Kovatchev, B. P., Casu, A., Pratley, R., Kanapka, L., & Beck, R. W. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261432166
Self-citationCausal mediation pathways in continuous postprandial glucose monitoring for type 1 diabetes patients
Hilligoss, S., & Qu, A. (2026) · npj Metabolic Health and Disease · doi:10.1038/s44324-026-00127-z
Lee, A.-H., Stokes, G., Farrell, K., & Holmes-Walker, D. J. (2026) · Diabetic Medicine · doi:10.1111/dme.70261
Валерьевич, П. В., Noskova, E. D., Kiyaev, A. V., & Detkov, V. Y. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-026
Artificial intelligence in cardiac drug delivery vehicles
Friuli, M., & Demitri, C. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40441-2.00010-x
Singh, R., Imberg, H., Ahmadi, S. S., Hallström, S., JENDLE, J. H., Tengmark, B.-O., Folino, A., Ekström, M., & Lind, M. (2026) · Scientific Reports · doi:10.1038/s41598-026-37158-x
González-Maroto, I., Moreno-Fernández, J., Beato-Víbora, P. I., & Quirós, C. (2026) · Diabetes & Metabolism · doi:10.1016/j.diabet.2026.101757
In Vitro and in Silico approach of continuous subcutaneous insulin infusion system reliability
Girardot, S. (2020) · theses.fr (ABES) · doi:10.70675/4f3118b9zebc2z40b9z9baczafa4dd39494c
Automated insulin delivery use in children and adolescents with type 1 diabetes across the world
Seget, S., Rusak, E., Pélicand, J., Fry, M., SHEANON, N. M., Schierloh, U. H. E., Xatzipsalti, M., Malinici, E. A., Tinti, D., Neylon, O. M., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113253 · Cited by 1
Editorial: Technologies for diabetes, volume III
Cardona‐Hernandez, R., Tinti, D., & Delvecchio, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1846249
Sobhani, N. C., Engle, K., & Rosenberg, E. A. (2026) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000993
Liu, M., Niu, F., Yovanovich, C., PUTCHA, V., SATHIYANATHAN, N. M. N., Kinnischtzke, A. K., Miller, D. M., Shin, J., Cordero, T. L., Vigersky, R. A., et al. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261441462
Succurro, E., Cersosimo, G., Sarnelli, P., Brisinda, F. M., Gattuso, I., Mazza, V., Fabiano, G., Iorio, F., Arena, R., Mazzitello, G., et al. (2026) · Acta Diabetologica · doi:10.1007/s00592-026-02690-9
Jenkins, J. G., Cocks, M. S., Lucas, S. J. E., Rendeiro, C., Peçanha, T., Maxwell, J., Tennant, J. H., Philpot, G., Narendran, P., Andrews, R., et al. (2026) · BMJ Open Sport & Exercise Medicine · doi:10.1136/bmjsem-2026-003240
Ehrmann, D., Roos, T., Kröger, J., Mühlen, H., Keuthage, W., Lueg, A., Scheper, N., Heinemann, L., Brandt, D., Hermanns, N., et al. (2026) · Journal of Diabetes Science and Technology · doi:10.1177/19322968261442286
Tatulashvili, S., Hamamouche, N., Sritharan, N., Servy, H., Fagherazzi, G., Riveline, J., Sablone, L., Bloch‐Queyrat, C., Joubert, M., & Cosson, E. (2026) · Diabetes & Metabolism · doi:10.1016/j.diabet.2026.101765
Mulley, J. F. (2026) · medRxiv · doi:10.64898/2026.05.13.26353094
Chernaya, M. E., Khalimov, Y. S., Volkova, A. S., Lisker, A. V., Nersesyan, A. A., Korotkova, E. V., & Obiedkova, Y. A. (2026) · Diabetes Mellitus · doi:10.14341/dm13366
Li, K., Shi, X., Zhang, L., Jiang, X., Liang, G., & Ding, Q. (2026) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_2239_25
Messaaoui, A., Hajselova, L., & Tenoutasse, S. (2026) · Acta Clinica Belgica · doi:10.1080/17843286.2026.2682344
Bisno, D. I., Turner, L. V., Gallop, R. J., KAMIMOTO, J. L. J., Reddy, S., Gal, R. L., Riddell, M. C., & Rickels, M. R. (2026) · Diabetes Care · doi:10.2337/dc26-0381
Vantomme, K., Dolatabadi, S., Sidhu, B., Hopman, W. M., & Houlden, R. L. (2026) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2026.05.009
First Use of Control-IQ+ Technology in Newly Indicated Populations
Assadi, K. Z., D’Souza, E. W., Pinsker, J. E., & Messer, L. H. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261456818
Self-citationInsulin Activity Varies Widely Across Equivalent Episodes of Hypoglycaemia in Type 1 Diabetes
Richardson, R. R. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71024
Kotan, R., Göçer, E. G., & Evren, B. (2026) · The International Journal of Artificial Organs · doi:10.1177/03913988261456923
Calhoun, P. M., Liggins, R., Li, Z., Riddell, M. C., Bergenstal, R. M., Simonson, G. D., Shah, V. N., Peers, S. H., Sherr, J. L., & Beck, R. W. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261461810
Self-citationSeliverstov, P. V., Shapovalov, V., Simakhodsky, A., Romakh, D., Dyakov, T., & Seliverstov, D. (2026) · Vrach · doi:10.29296/25877305-2026-06-01
Safiullina, A. N. (2026) · International Conference on Artificial Intelligence for Sustainable Engineering and Innovation (AISEI) · doi:10.1109/aisei68628.2026.11572851
Real‐world outcomes using the Tandem Mobi insulin pump with Control‐ IQ + technology and Dexcom G7
D’Souza, E. W., Castle, J. R., Assadi, K. Z., Messer, L. H., & Pinsker, J. E. (2026) · Diabetic Medicine · doi:10.1111/dme.70413
Self-citationŠantová, A., Neuman, V., Amaratunga, S. A., Drnkova, L., Kavčiak, L., Neumanová, M., Jagiellová, E., Nesvadbova, M., Koloušková, S., Obermannová, B., et al. (2026) · Diabetic Medicine · doi:10.1111/dme.70402
Perceptions of adults with type 1 diabetes mellitus about diabetes management and exercise
Swaminath, M., Griggs, S. A., Lukasik, J., Spanakis, E. K., Kinney, R. L., & Ash, G. I. (2026) · Human Factors in Healthcare · doi:10.1016/j.hfh.2026.100146
Sleep Health and Barriers in Adolescents with Type 1 Diabetes: A Mixed-Methods Study
Cobry, E. C., Fivekiller, E. E., Pyle, L., Meltzer, L. J., Jaser, S. S., TAYLOR, K., Rasmussen, C. G., Stewart, B., & Wadwa, R. P. (2026) · Hormone Research in Paediatrics · doi:10.1159/000553441
Self-citationCai, H., He, Y. F., Wang, C., Zhao, Y., & Yang, C. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1885022 · Cited by 1
Current diabetes drugs: Lessons learned and implications for next-generation therapeutics
Liao, J., Cong, Z., Liu, K., Que, H., & Liu, F. (2026) · The Innovation Drug Discovery · doi:10.59717/j.xinn-drugdisc.2026.100008
Horton, W. B., Anderson, K. C., Love, K. M., Jahn, L. A., Hartline, L. M., Patrie, J. T., Liu, J., Solga, M. D., Awan, W. J., Thakur, A., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06806-2
Marigliano, M., Piona, C. A., Morotti, E., Macedoni, M., Kharazizadeh, P., Mancioppi, V., Tomasselli, F., Tommasi, M., & Maffeis, C. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71135
From algorithm to alarm: a narrative review on insulin delivery innovation
Saleem, N. U. A., Arshad, F., Qadri, M., Mushtaq, M. S., Khan, M., Shakoor, P., Patel, T., Noor, A., Sardarova, N., Anand, N., et al. (2026) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000005307
Advanced Technology in Diabetes: Sensors and Pumps
Forlenza, G. P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-11985-9.00023-8
Self-citationYamaoka, T., Sugiyama, T., Kashiwagi, K., Furuno, T., Yamamoto, K., Imai, K., Ihana‐Sugiyama, N., Nishioka, Y., Ohsugi, M., Ueki, K., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113462
INSIGHT: Ingest and Standardize Glucose Harmonization Tool
Ehlert, B., -, K. S., Katarya, D., Wu, Y., Wang, T., & Snyder, M. P. (2026) · Journal of Diabetes Science and Technology · doi:10.1177/19322968261467778
Bach, E., Fisker, S., Christensen, M., Bibby, B. M., & Hansen, K. W. (2026) · Journal of Diabetes Science and Technology · doi:10.1177/19322968261471164
Mirto, F. O. (2026) · IEEE International Conference on Smart Computing Workshops and Other Affiliated Events (SMARTCOMP Companion) · doi:10.1109/smartcomp-companion70724.2026.00094
Eroğlu, A. G., Özgür, B. A., ŞENTÜRK, N. G. K., Karakaş, A., Celik, S. C., Kara, B., Turan, H., Bayramoğlu, E., & Evliyaoğlu, O. (2026) · Echocardiography · doi:10.1111/echo.70563
Real-World Outcomes of Automated Insulin Delivery Use in Hospitalized Adults With Diabetes
Ruddiman, K. R., Evans, J. K., Aloi, J., Usoh, C. O., & Price, C. E. (2026) · Journal of Diabetes Science and Technology · doi:10.1177/19322968261473583
范若竹, & Wu, X. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1904561
Roy, N., Powers, M., Gonzalez, M., & Cucullo, L. (2026) · Biosensors · doi:10.3390/bios16090477
Baravkar, A., Dhawan, A., Bhondwe, Y. Y., & SHINDE, S. D. (2026) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2026.111248
Kodani, N. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70423
PERKINS, A. G., Straton, E., Majidi, S., Barber, J., Maya, G., WHITE, S., Naveed, M., & Streisand, R. M. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doc26-0055
Struckmeyer, N., Landsberg, S., Biester, T., Dolle, R. M., Frerking, A.-K., Kapitzke, K., Knottnerus-Meyer, N., Niemeyer, M., Toenne, R., Berge, T. V. D., et al. (2026) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2026-0309
Diabetes Technology in Children
Zhou, Y., & Wheeler, B. J. (2026) · Springer eBooks · doi:10.1007/978-3-032-24854-1_14
Initiation of Continuous Glucose Monitoring and Insulin Pump Therapy
Hindmarsh, P. C., Gupta, A., Swart, A., & Cooper, A. (2026) · Springer eBooks · doi:10.1007/978-3-032-24854-1_6
The Role of Artificial Intelligence in Diabetes Care
PATANGE, S. A., Wallace, A., & Gupta, S. (2026) · Springer eBooks · doi:10.1007/978-3-032-24854-1_19
Insulin Delivery and Technology
Parab, R., & Shirke, M. (2026) · Springer eBooks · doi:10.1007/978-3-032-24854-1_5
Lu, B., Wagle, B., Zhaohui, L., Cui, Y., & Prioleau, T. (2026) · PLOS Digital Health · doi:10.1371/journal.pdig.0001633 · Cited by 1
Liu, V. B., Pho, M., & Wu, Y. N. (2026) · Mathematics in Medical and Life Sciences · doi:10.1080/29937574.2026.2705548
Kitsios, K., & Trakatelli, C. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261486127
Smart Pharmaceutical Systems: Sensor-Enabled Delivery, Feedback Control, and Therapeutic Autonomy
Benali, A., Boudiaf, K., & Touati, S. (2026) · Journal of Applied Pharmaceutical Technologies and Systems · doi:10.68159/f721269020
Metadata
- Authors
- Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., Dassau, E., Doyle, F. J., Anderson, S. M., Church, M. M., Dadlani, V., Ekhlaspour, L., Forlenza, G. P., Isganaitis, E., Lam, D. W., Kollman, C., & Beck, R. W.
- Affiliations
- Sansum Diabetes Research Institute (US)
- Mayo Clinic (US)
- Joslin Diabetes Center (US)
- Harvard University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-10-31
- Volume
- 381
- Issue
- 18
- Pages
- 1707-1717
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7076915
- OpenAlex
- W2981310284
- Semantic Scholar
- a8aee7f3c717498afd65ea39bd87dd1c1ea5d693
- Cited by
- 1,030
- References
- 17
- Citations by year
- 2026: 128 · 2025: 134 · 2024: 140 · 2023: 180 · 2022: 158 · 2021: 156 · 2020: 125 · 2019: 8
- FWCI
- 90.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (UC4 DK108483)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 1 diabetes, artificial pancreas, sensor-augmented pump, continuous glucose monitoring, glycemic control, HbA1c, hypoglycemia, hyperglycemia, insulin pump therapy, glycemic variability, HbA1c reduction, hypoglycemia risk reduction, HbA1c thresholds, hypoglycemia risk
- MeSH terms
- Adolescent, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 1, Equipment Design, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Male, Middle Aged, Pancreas, Artificial, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
